Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $36.90

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) have earned a consensus rating of “Moderate Buy” from the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $36.90.

Several research firms have recently issued reports on SNDX. JPMorgan Chase & Co. increased their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. UBS Group started coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They issued a “buy” rating and a $37.00 price objective for the company. The Goldman Sachs Group increased their target price on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Finally, Citigroup boosted their price target on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th.

Hedge Funds Weigh In On Syndax Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Simplify Asset Management Inc. lifted its stake in Syndax Pharmaceuticals by 62.5% in the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company’s stock worth $2,352,000 after purchasing an additional 46,992 shares in the last quarter. Franklin Resources Inc. increased its holdings in shares of Syndax Pharmaceuticals by 13.4% in the third quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock valued at $34,948,000 after purchasing an additional 208,043 shares during the last quarter. State Street Corp lifted its position in Syndax Pharmaceuticals by 4.1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after buying an additional 148,491 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Syndax Pharmaceuticals by 6.3% during the third quarter. Charles Schwab Investment Management Inc. now owns 695,947 shares of the company’s stock worth $13,397,000 after buying an additional 41,458 shares during the last quarter. Finally, Barclays PLC grew its holdings in Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock valued at $3,612,000 after buying an additional 110,535 shares in the last quarter.

Syndax Pharmaceuticals Trading Up 5.6 %

Shares of NASDAQ:SNDX opened at $13.22 on Friday. Syndax Pharmaceuticals has a 12-month low of $12.40 and a 12-month high of $25.34. The business has a 50 day moving average of $16.25 and a two-hundred day moving average of $18.87. The company has a market capitalization of $1.13 billion, a PE ratio of -3.64 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the prior year, the firm earned ($0.73) earnings per share. Equities research analysts predict that Syndax Pharmaceuticals will post -2.39 earnings per share for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).